I write to ask if now the time is to make the case for reclassifying the MPharm degree as a vocational qualification, reflecting the realities of contemporary healthcare practice and providing a longer academic year that allows capacity for increased experiential learning.
The role of the pharmacist has evolved markedly. Pharmacists practise as clinicians across community, hospital and primary care settings, with increasing responsibility for complex direct patient care, including as prescribers. These expanded roles demand not only scientific expertise but pharmacists who are comfortable making evidence-informed decisions in situations that are incomplete, evolving or nuanced.
If we are serious about preparing graduates for this reality, we must ask whether experiential learning should be substantially expanded and embedded from the first year of undergraduate study. Early and sustained exposure to authentic clinical settings would allow students to contextualise academic knowledge and progressively build confidence in ‘working in the grey’. As prescribing and advanced clinical decision-making become central to practice, comfort with uncertainty is essential. Extended, structured, longitudinal placements could reduce aversion to ambiguity, strengthen professional identity and enhance patient safety.
Confidence in navigating ambiguity and comfort with risk cannot be fully developed through classroom learning alone — it is cultivated over time through supervised practice, reflection and graded responsibility. Given this, should the MPharm degree continue to be framed primarily as an academic scientific programme, or is a vocational classification more consistent with its intent and outcomes as is the case in medicine, nursing and other healthcare professions?
A vocational classification could support this shift in a practical way. It would enable an expanded academic year of approximately eleven months, rather than the current model of around seven months. This would not require removal of existing curricular content; rather, it would create additional, protected time for meaningful experiential learning alongside the established scientific foundation. In doing so, it would add to, rather than dilute, the current curriculum.
It is recognised that such a transition would require careful consultation, time and significant investment. Funding constraints and placement capacity present genuine challenges. However, should these barriers prevent the profession from beginning the conversation and lobbying government? Or is this precisely the moment to consider whether the existing framework remains fit for purpose?
The question is not whether change would be straightforward but whether evolving practice now makes it necessary.
Bruce Warner
Candidate for the National Pharmacy Advisory Council for England
You may also be interested in
Representation matters
Patient safety must keep pace with expanding clinical scope
